Pericarditis Drugs Market Report 2026

The pericarditis drugs market size has grown strongly in recent years. It will grow from $3.31 billion in 2025 to $3.61 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increasing diagnosis rates of inflammatory cardiac conditions, availability of established NSAID therapies, expansion of cardiology care infrastructure, growing use of colchicine-based treatments, improved clinical guidelines.

The pericarditis drugs market size is expected to see strong growth in the next few years. It will grow to $5.1 billion in 2030 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to increasing development of biologic and immunomodulatory drugs, rising focus on personalized cardiac care, expansion of outpatient and homecare treatment models, growing investment in cardiovascular research, increasing awareness of rare inflammatory heart diseases. Major trends in the forecast period include increasing adoption of targeted anti-inflammatory therapies, rising use of combination drug regimens, growing focus on recurrent pericarditis management, expansion of hospital-based treatment protocols, enhanced monitoring of treatment outcomes.

The rising prevalence of autoimmune diseases is expected to drive the growth of the pericarditis drugs market in the coming years. Autoimmune diseases are conditions where the immune system mistakenly attacks the body’s own healthy cells and tissues. This increasing prevalence is mainly influenced by environmental factors that disrupt the immune system, causing it to target healthy tissues. Pericarditis drugs are important in the context of this trend, as many autoimmune conditions can lead to pericarditis, an inflammation of the heart’s lining. These drugs help reduce inflammation, alleviate symptoms, and prevent complications, thereby managing pericarditis that results from autoimmune activity. For example, in September 2023, according to the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canada-based organization focused on improving the lives of patients with Crohn's disease and ulcerative colitis, the prevalence of IBD was 825 per 100,000, with over 320,000 people affected in Canada. With an expected annual increase of 2.44%, or 1.1% of the population, approximately 470,000 Canadians are projected to be living with IBD by 2035. Thus, the growing prevalence of autoimmune diseases is contributing to the expansion of the pericarditis drugs market.

The increasing demand for personalized medicine is expected to drive the growth of the pericarditis drugs market in the coming years. Personalized medicine is a healthcare approach that tailors disease prevention and treatment according to an individual’s specific genes, behaviors, and environment. The growing interest in personalized treatments is fueling the expansion of personalized medicine, as patients and healthcare providers increasingly seek therapies customized to individual genetic and lifestyle profiles for enhanced effectiveness and minimized side effects. This demand for personalized medicine also drives the need for pericarditis drugs, as it allows for the development of targeted therapies designed according to an individual’s genetic and biological profile, resulting in more precise and effective treatment of pericardial inflammation. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the FDA approved 16 personalized therapies targeting rare diseases in 2023, a significant increase from the six approvals issued in 2022. Thus, the growing demand for personalized medicine is supporting the expansion of the pericarditis drugs market.

Major companies operating in the pericarditis drugs market are focusing on developing innovative products, such as oral anti-inflammatory therapies to enhance treatment accessibility and reduce recurrence rates in patients with recurrent pericarditis. An oral anti-inflammatory therapy is a small-molecule formulation designed to modulate inflammatory pathways and prevent disease relapse through systemic, non-injectable administration. For instance, in April 2025, Cardiol Therapeutics Inc., a Canada-based clinical-stage life sciences company specializing in anti-inflammatory and anti-fibrotic therapies for heart diseases, initiated a Phase III clinical trial for CardiolRx. The investigational therapy is designed to target inflammasome pathway activation, a central mechanism in pericarditis-related inflammation and fibrosis. Its development marks progress toward offering a convenient, oral, non-immunosuppressive treatment option that could broaden therapeutic choices for recurrent pericarditis patients.

Major companies operating in the pericarditis drugs market are Merck & Co. Inc., Pfizer Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Hikma Pharmaceuticals USA Inc., Zydus Lifesciences Limited, Kiniksa Pharmaceuticals, Camber Pharmaceuticals Inc., Scilex Holding Company, Solara Active Pharma Sciences, Alkaloids Bioactives Pvt. Ltd., Alchem International Pvt. Ltd., Sarv Biolabs Pvt. Ltd., Midas Pharma GmbH, AdvaCare Pharma, Actavis GmbH, Enomark LLC, Honour Lab Limited.

North America was the largest region in the pericarditis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pericarditis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pericarditis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the pericarditis drugs market by increasing costs of imported active pharmaceutical ingredients, excipients, biologic compounds, and sterile manufacturing inputs. Europe and North America are most affected due to dependence on global API supply chains, while Asia-Pacific faces cost pressures on pharmaceutical exports. These tariffs are contributing to higher drug production costs and influencing hospital procurement budgets. However, they are also encouraging domestic API manufacturing, regional supply chain diversification, and increased investment in localized pharmaceutical production capabilities.

The pericarditis drugs market research report is one of a series of new reports that provides pericarditis drugs market statistics, including pericarditis drugs industry global market size, regional shares, competitors with a pericarditis drugs market share, detailed pericarditis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the pericarditis drugs industry. This pericarditis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pericarditis drugs are medications designed to treat inflammation and pain in the pericardium, the membrane surrounding the heart. They work by regulating inflammatory responses and relieving discomfort, supporting normal heart function and preventing additional complications. Healthcare professionals prescribe and monitor these drugs to ensure effective treatment while minimizing potential side effects.

The main drug classes in pericarditis treatment include nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, corticosteroids, and others. Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to reduce inflammation, relieve pain, and lower fever in pericarditis by inhibiting cyclooxygenase enzymes involved in prostaglandin production. These drugs can be administered orally, intravenously, intramuscularly, or topically, and are distributed through channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. They are applied in therapeutic areas including acute pericarditis treatment, management of recurrent pericarditis, post-cardiac surgery care, and pericardial effusion management. The primary end users include hospitals, homecare services, specialty clinics, and others.

The pericarditis drugs market consists of sales of antitubercular drugs, receptor antagonists, rilonacept, antibiotics or antifungals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.